HemaSphere Journal

Clarivate has released the final-final 2023 #ImpactFactors & we're thrilled to have earned a place on the top-10 hematology journals stage. While we celebrate and offer gratitude, it is our continued aim that we also make a wider impact in the hematology community beyond this benchmarking data. 🎤 https://lnkd.in/eCZiArdn

🎧New HemaSphere Podcast Episode! In the latest episode, Dr Charles de Bock talks with Prof H. Josef Vormoor and Dr Maria Ester Bernardo, Chair and Co-Chair of EHA’s Pediatric Hematology Specialized Working Group. They discuss highlights from the EHA 2024 Congress in Madrid, including key lectures, new insights and what they could mean for clinicians, researchers, patients and their families, along with hopes and expectations for the EHA2025 Congress in Milan.  “Best of Pediatric Hematology from EHA2024”, is on our website https://lnkd.in/eAm2yQAR , all major podcast platforms (Spotify, Apple Podcast, and more), and our YouTube channel. Listen and enjoy casual, insightful discussions about #hematology research.  We are pleased to offer HemaSphere’s full listing of publications about pediatric hematology, now in a dedicated collection. This online collection will be added to monthly 👉 https://bit.ly/4eQmptj

ERIC, the European Research Initiative on CLL, conducted this international multicenter retrospective study  focused on the era of CIT with 2 goals: reveal the treatment patterns in the “real world” and assess the outcomes of patients who received frontline treatment from 2000 through 2016.  Read about the results here👉https://bit.ly/3NuiSpf

HemaTopics are HemaSphere publications focusing on hot hematology topics including recent research developments, updates on diagnosis and treatment, policy and guidelines news, and more. This week we focus on the latest HemaTopic by Scientific Editor S Hibbs,  a thought provoking discussion on our consent practices, and that may be acceptable within legal and bureaucratic norms, but how often do patients truly understand the treatments we recommend and prescribe? Read more here👉https://bit.ly/3yfnOKx

🏆 Each month HemaSphere Chief Editor Prof Jan Cools selects Editor Highlights, which he calls out as new, must-read papers. We invite you to read, download, share, and cite this month’s Editor’s Highlight pick👉 https://bit.ly/4epSxEh

This recently published Review discusses the physiological and pathological molecular mechanisms of wild-type and fusion forms of the NUP98 protein, along with the genomic landscape of NUP98 fusion-driven leukemia and highlight prospective treatment options for this AML subtype 👉https://bit.ly/3NuiSpf

The lower proportions and altered transcriptome properties of myeloid-derived suppressor cells in chronic idiopathic neutropenia probably contribute to the sustained inflammatory process. Read more about it in the latest issue 👉https://bit.ly/3XNMOkO

📰 EHA Guidelines create and provide clinical practice recommendations for the diagnosis and treatment of hematologic diseases. These are based on the best available evidence and expert consensus that can support the appropriate choice of diagnostic procedures and/or therapeutic interventions in the field of hematology. This week we highlight a recent joint EHA – ESMO guidelines publication on HIV-associated lymphomas 👉https://bit.ly/3zg0Gfc

🏆 Each month HemaSphere Chief Editor Prof Jan Cools selects Editor Highlights, which he calls out as new, must-read papers. We invite you to read, download, share, and cite this month’s Editor’s Highlight pick👉https://bit.ly/3Y5MDm1

Read this latest HemaBites: Did you know the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) publicly releases its monthly meeting highlights? We are pleased to alert you to this important information, and to specifically feature the hematology-related updates from the committee. #CHMP #EMA #EHA